miR-1267 Induces Tumorigenicity and Contributes to Risk of Clear Cell Renal Cell Carcinoma
Abstract
Objective: Dysregulated microRNA signatures in different cancer types are being uncovered continually implying their significance in cancer pathogenesis. miR-1267 was not previously associated with RCC. In this study, it is aimed to obtain the expression profile of miR-1267 in patients with ccRCC and its correlation with patient parameters.
Methods: Kidney Cancer cDNA Array consisting of cDNA samples obtained from healthy kidney tissues of 4 healthy individuals and tumoral kidney tissues of 5 Stage I, 5 Stage II, 3 Stage III and 2 Stage IV ccRCC patients was used. Hsa-miR-1267 and SNORD48 (as housekeeping gene) expressions were analyzed. miR-1267 expression was statistically correlated with the clinical parameters of patients. miRGator 3.0 database was used to compare miR-1267 expression patterns of different urological cancer types.
Results: The expression of miR-1267 was significantly higher in male than female (p=0.027). Also, there were statistically significant increase in miR-1267 expression in stage IV when compared to stage I (p<0.001). Moreover, increased platelet/lymphocyte ratio and calcium level, which were parameters giving information about the occurrence of ccRCC, are significantly associated with increased miR-1267 expression (p<0.001 and p=0.003, respectively). The expression of miR-1267 in kidney tumor tissues was higher approximately three times than normal kidney tissues (p>0.05).
Conclusion: miR-1267 could have oncogenic function, have predictive value for RCC development and be predictive about aggressiveness in ccRCC.
Keywords
References
- Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128.
- Barrey E, Saint-Auret G, Bonnamy B, Damas D, Boyer O, Gidrol X. Pre-microRNA and mature microRNA in human mitochondria. PLoS One 2011; 6: e20220.
- Cho S, Jang I, Jun Y, Yoon S, Ko M, Kwon Y, et al. MiRGator v3. 0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res 2012; 41: D252-D57.
- Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-79.
- Kowalczyk AE, Krazinski BE, Godlewski J, Grzegrzolka J, Kiewisz J, Kwiatkowski P, et al. SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis. Cancer Genomics Proteomics 2016; 13: 209-17.
- Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 2013; 23(1): 3-9
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-30.
- Park TJ, Cho YH, Chung HS, Hwang EC, Jung SH, Hwang JE, et al. Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. Springerplus 2016; 5(1):1889.
- Protzel C, Maruschke M, Hakenberg OW. Epidemiology, aetiology, and pathogenesis of renal cell carcinoma. Eur Urol Suppl 2012; 11: 52-59.
- Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Reanl Physiol 2017; 313: F145-F54.